Chronic News and Research

RSS

Unani.ca consumer-minded PEHR now available in Canadian marketplace

The McGill University Health Centre announced today that anyone with an Internet access and a desire to manage his or her health and well-being can now subscribe to Unani.ca. Co-developed with Quebec-owned Medical.MD, Unani.ca is the first consumer-minded personal electronic health record (PEHR) in the Canadian marketplace that combines the expertise of a world-class academic health centre with that of award-winning information-technology developers.

16 Mar 2010

Savient Pharmaceuticals resubmits KRYSTEXXA BLA

Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

16 Mar 2010

Gardasil vaccine: Two complaints filed in Washington Federal Claims court

Anapol Schwartz attorneys Lawrence Cohan and Melissa Fry Hague recently filed two Gardasil vaccine complaints – one on behalf of a Kensington, Calif., family, whose 15-year old daughter died after suffering from severe adverse reactions, and another on behalf of a 19-year old Lapeer, Mich., woman, who has a chronic, autoimmune disorder. The cases, filed in The Court of Federal Claims in Washington, D.C., seek recovery under the National Vaccine Injury Compensation Program.

15 Mar 2010

Vertebroplasty: Patient selection vital

Patient selection is key for vertebroplasty—a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy—to be effective and successful, according to a study of more than 1,500 persons who were followed over seven years. Additionally, collaboration between an interventional radiologist and other medical experts in treating a patient is imperative, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

Cook Medical launches new NavAlign femoral delivery system at SIR Annual Scientific Meeting

Physicians placing inferior vena cava (IVC) filters to prevent life-threatening pulmonary emboli now have access to the latest iteration of Cook Medical’s advanced NavAlign™ delivery system, a deployment system designed to minimize the risk of vessel trauma and streamline filter placement.

15 Mar 2010

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

Hemispherx Biopharma, Inc., announced its financial results for the fiscal year ended December 31, 2009. The net loss for the year (including non-cash charges) was approximately $13,438,000 or $0.12 per share as compared to a net loss of $12,219,000 or $0.16 per share in 2008.

15 Mar 2010

MBGH conduct national survey to improve employer-based health improvement and management programs

To better understand and improve the effectiveness of employer-based health improvement and management programs, the Midwest Business Group on Health, conducted a national survey of physician views on employers' health management programs.

15 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

Presence of plaque on abdominal CT scan: Strong predictor of coronary artery disease and mortality

The presence of plaque on an abdominal CT scan is a strong predictor of coronary artery disease and mortality, according to a Henry Ford Hospital study.

15 Mar 2010

Study reveals molecular mechanism of pancreatic cancer

UCSF scientists have discovered how a mutated gene known as Kras is able to hijack mouse cells damaged by acute pancreatitis, putting them on the path to becoming pancreatic cancer cells.

15 Mar 2010

Discovery may yield new strategies for blocking malaria transmission

Scientists studying the Anopheles gambiae mosquito - the main vector of malaria - have found that when the mosquito takes a blood meal, that act triggers two enzymes to form a network of crisscrossing proteins around the ingested blood.

15 Mar 2010

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

Telemonitoring may reduce mortality of heart failure patients by 20%

Telemonitoring may reduce the mortality of patients with heart failure by 20%. Silke Schmidt et al. present their study results in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]131-8).

12 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

Managing back pain without costly medications: High-touch Integrative Medicine therapies may help

A new pilot study conducted with assembly workers at the Ford Motor Company in Louisville, KY focused on acute, work-related low back pain. Results of that study indicate that high-touch Integrative Medicine (IM) therapies can help employees manage back pain without the costly medications typically associated with managing their pain.

12 Mar 2010

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical.

From Baxter International Inc. 12 Mar 2010

New molecule effective against lice

French medical researchers from the AP-HP (Henri Mondor Hospital and Avicenne Hospital) and Inserm (Unit 738 "Models and methods for therapeutic evaluation of chronic illnesses" and CIC 202, at Tours) have recently demonstrated the effectiveness of a new molecule in the fight against lice. Faced with the emergence of increasing resistance to conventional treatments by these parasites, this new medication represents a real therapeutic alternative which is effective in 95% of cases.

12 Mar 2010

Chronic News and Research

Unani.ca consumer-minded PEHR now available in Canadian marketplace

Savient Pharmaceuticals resubmits KRYSTEXXA BLA

Gardasil vaccine: Two complaints filed in Washington Federal Claims court

Vertebroplasty: Patient selection vital

Cook Medical launches new NavAlign femoral delivery system at SIR Annual Scientific Meeting

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

MBGH conduct national survey to improve employer-based health improvement and management programs

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Presence of plaque on abdominal CT scan: Strong predictor of coronary artery disease and mortality

Study reveals molecular mechanism of pancreatic cancer

Discovery may yield new strategies for blocking malaria transmission

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Telemonitoring may reduce mortality of heart failure patients by 20%

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

New MMMCC center improves patients’ access to medical marijuana

Managing back pain without costly medications: High-touch Integrative Medicine therapies may help

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

New molecule effective against lice

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News